UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code:
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1034 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Effective as of October 5, 2021, ChemoCentryx, Inc. (the “Company”) appointed Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer of the Company. Dr. Jain will report to the Company’s President and Chief Executive Officer.
Dr. Jain, 59, has served as a member of our board of directors (“Board”) since March 2019. From January 2021 to June 2021, Dr. Jain served as Chief Medical Officer of Immunovant, Inc. From May 2017 until June 2019, Dr. Jain served as Senior Vice President and Chief Medical Officer of Akebia Therapeutics, Inc., a biotechnology company. Prior to joining Akebia, Dr. Jain was Vice President of Men’s and Women’s Health and Metabolic Development at AbbVie, Inc. From 2003 to 2016, Dr. Jain served in various leadership roles including Divisional Vice President at Abbott Laboratories. Dr. Jain led the design and execution of multiple late-stage programs, including for Orilissa® and Oriahnn®. She has also led programs across a diverse set of therapeutic areas including inflammation, pain, immunology and nephrology, among others. Before Abbott, she held management positions in the Arthritis, Inflammation and Pain Group at G.D. Searle (acquired by Pharmacia and subsequently Pfizer). Prior to joining G.D. Searle, Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, New York University School of Medicine. Dr. Jain received her B.S. in biology from LIU/C.W. Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.
In connection with her appointment as Executive Vice President, Chief Medical Officer, the Company entered into an offer letter with Dr. Jain (the “Jain Offer Letter”) setting forth the terms of her employment and compensation. Pursuant to the Jain Offer Letter, Dr. Jain’s annual base salary will be $525,000, and she will be eligible to participate in the Company’s Corporate Bonus plan with a target amount of up to 50% of her gross annual salary in effect during the bonus year, based upon factors, including, but not limited to, individual and Company performance and compliance with Company policies and procedures (with the bonus for 2021 being pro-rated for the time that Dr. Jain was employed as Executive Vice President, Chief Medical Officer by the Company). In addition, pursuant to the Jain Offer Letter, Dr. Jain will receive an option to purchase 45,000 shares of the Company’s common stock (the “Jain Option”), subject to and following approval by the Board, pursuant to the Company’s 2012 Equity Incentive Plan. The per share exercise price of the Jain Option is equal to $19.00, the per share fair market value of the Company’s common stock on October 5, 2021 (as determined by the Company’s Compensation Committee as of October 5, 2021). In addition, Dr. Jain will be eligible for certain employee benefits available generally to employees of the Company pursuant to the terms of such benefit plans maintained by the Company.
In the event that the Company terminates Dr. Jain without cause, at any time other than on or within twelve months following the effective date of a change of control, the Company will pay her a cash amount equal to twelve months of her then current base salary in effect at the time of her termination paid over a period of twelve months following her termination in accordance with the Company’s standard payroll practices. If Dr. Jain elects, the Company will provide continuation of group health plan benefits to the extent authorized by and consistent with COBRA or applicable state law (the “COBRA Termination Option”), with the cost of regular payment for such benefits paid by the Company as was in effect on the date of her termination until the earlier of (i) the close of the twelve month period following termination of employment; (ii) the expiration of Dr. Jain’s eligibility for the continuation coverage under COBRA; or (iii) the date Dr. Jain becomes eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment. Dr. Jain is also entitled to acceleration of the service-based vesting of the Jain Option and any other equity grants she may hold as of the date of termination, to the extent then outstanding, unvested and, if applicable, unexercised or unsettled, and as to the number of shares subject to such equity grants that would have vested in accordance with the applicable service-based vesting schedule as if she had been in service for an additional twelve months as of the termination date.
In the event that the Company terminates Dr. Jain without cause, at any time on or within twelve months following the effective date of a change of control, the Company will pay her a lump sum cash amount equal to twelve months of her then current base salary in effect at the time of her termination and a lump sum cash payment consisting of an amount equal to her target annual bonus, with such bonus determined assuming all applicable performance objectives were obtained at target levels for the applicable year. Dr. Jain also has the option to elect the COBRA Termination Option. Dr. Jain is also entitled to acceleration of the service-based vesting of the Jain Option and any other equity grants she may hold as of the date of termination, to the extent then outstanding, unvested and, if applicable, unexercised or unsettled, such that she will be deemed fully vested as to the service-based vesting requirement thereof as of the termination date.
All of the severance benefits are subject to, among other things, Dr. Jain continuing to comply with her obligations under her Confidential Information Agreement and the execution and delivery of a general release of claims in favor of the Company.
The foregoing description of the Jain Offer Letter does not purport to be complete and are subject to, and qualified in its entirety by reference to the full text of the Jain Offer Letter copy of which are attached hereto as Exhibit 10.1.
There are no family relationships between Dr. Jain and any of our directors or executive officers. Except as set forth herein, there is no arrangement or understanding between Dr. Jain and any other persons pursuant to which Dr. Jain wasappointed as Executive Vice President, Chief Medical Officer of the Company. There are no related party transactions involving Dr. Jain that are reportable under Item 404(a) of Regulation S-K.
Item 8.01 Other Events
On October 11, 2021, the Company issued a press release announcing the appointment of Dr. Jain as the Company’s Executive Vice President, Chief Medical Officer. A copy of the press release is attached hereto as Exhibit 99.1, which is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
10.1 | Offer Letter between the Company and Rita I. Jain, dated October 5, 2021 | |
99.1 | Press release, dated October 11, 2021. | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHEMOCENTRYX, INC. | ||||||
Date: October 11, 2021 | ||||||
By: | /s/ Susan M. Kanaya | |||||
Name: Susan M. Kanaya | ||||||
Title: Executive Vice President Chief Financial and Administrative Officer and Secretary |
Exhibit 10.1
October 5, 2021
Rita I. Jain, M.D.
Dear Rita:
On behalf of ChemoCentryx, Inc. (ChemoCentryx or the Company), I am pleased to offer you employment as Executive Vice President, Chief Medical Officer. In this position, you will report to Thomas Schall, President and Chief Executive Officer, and will work from your Chicago, Illinois location while travelling regularly to ChemoCentryx headquarters in San Carlos, California (average one week or more per month).
Compensation & Benefits
Your initial annual base salary will be $525,000.00 less applicable deductions and withholdings, which will be paid semi-monthly in accordance to the Companys normal payroll procedures. As an exempt employee, you will be required to work the Companys normal business hours and additional hours as required by the nature of your work assignments, and you will not be entitled to payment of overtime. You are also eligible for certain employee benefits available generally to employees of ChemoCentryx pursuant to the terms of such benefit plans. You should note that ChemoCentryx may modify salaries, benefits, duties, titles, reporting relationships, and work locations from time to time at its discretion.
You will be eligible to participate in the ChemoCentryx Corporate Bonus plan, and your target award opportunity is 50% of your gross annual salary in effect during the bonus year (the Annual Bonus). Actual payment of the Annual Bonus will be based upon factors including, but not limited to, individual and Company performance and compliance with Company policies and procedures. During your first partial year of employment, your Annual Bonus target amount will be prorated based on your date of hire. You must be an active ChemoCentryx employee in good standing (e.g. not subject to an active compliance investigation, verbal counseling, any written warning, or a performance improvement plan) as of the date of any Annual Bonus is paid in order to earn the bonus. The Company will have the sole discretion to determine whether and to what extent the applicable corporate and individual goals and other bonus criteria have been achieved, and the amount of any awarded Annual Bonus.
Subject to and following approval by the Companys Board of Directors (the Board) or a committee thereof, the Company shall grant you an option to purchase 45,000 shares of the Companys common stock (subject to stock splits and similar adjustments) with a per share exercise price equal to the per share fair market value of the Companys common stock on the date of grant (as determined by the Board or a committee thereof as of the date of grant) (the Option) pursuant to the Companys 2012 Equity Incentive Plan (the Plan). The Option will be governed in full by the terms and conditions of the Plan and your individual grant agreement, including the service-based vesting schedule and requirements set forth therein.
Page 1 of 6
Offer of Employment: Rita I. Jain, M.D.
Policies/Confidential Information
As a condition of your employment you will abide by the Companys policies and procedures, including but not limited to the policies set forth in the Companys Employee Handbook, as may be in effect from time to time. You will be required to sign an acknowledgement that you have read and will comply with the policies contained in the Employee Handbook. You also must read, sign, and comply with the Companys Employee Confidential Information and Inventions Assignment Agreement (the Confidential Information Agreement), attached here as Exhibit A. In your work for the Company, you are expected not to make unauthorized use or disclosure of any confidential or proprietary information or materials, including trade secrets, of any former employer or other third party to whom you have an obligation of confidentiality. By signing this letter, you represent that you are able to perform your job duties within these guidelines, and you are not in unauthorized possession of any confidential documents or other property of any former employer or other third party. You further represent that you have disclosed to the Company in writing any agreement you may have with any third party (e.g., a former employer) which may conflict with or limit your ability to perform your duties to the Company.
At-Will Employment; Severance
ChemoCentryx is pleased about your joining and looks forward to a beneficial and fruitful relationship. Nevertheless, you should be aware that your employment is not for a specified period of time, it is terminable at-will by either party. This means that you may terminate your employment with the Company at any time and for any reason whatsoever simply by notifying us. Likewise, the Company may terminate your employment at any time, with or without Cause, and with or without advance notice, simply by notifying you.
If, at any time, the Company terminates your employment for Cause (as defined in Exhibit C), or if either party terminates your employment as a result of your death or disability, or you resign for any reason, you will receive your base salary accrued through your last day of employment, as well as any unused vacation (if applicable) accrued through your last day of employment. Under these circumstances, you will not be entitled to any other form of compensation from the Company, including any severance benefits.
If, at any time other than on or within 12 months following the effective date of a Change in Control (as defined in Exhibit C), the Company terminates your employment without Cause, and other than as a result of your death or disability, and provided such termination constitutes a separation from service (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a Separation from Service), then subject to your obligations below, you shall be entitled to receive the following severance benefits (collectively, the Non-CIC Severance Benefits):
(i) a cash amount equal to twelve (12) months of your then current base salary, less all applicable withholdings and deductions, paid over such twelve (12) month period, on the schedule described below (the Salary Continuation);
(ii) if you timely elect continued coverage under COBRA for yourself and your covered dependents under the Companys group health plans following such termination or resignation of employment, then the Company shall pay the COBRA premiums necessary to continue your health insurance coverage in effect for yourself and your eligible dependents on the termination date until the earliest of (A) the close of the twelve (12) month period following the termination of your employment, (B) the expiration of your eligibility for the continuation coverage under COBRA, or (C) the date when you become eligible for substantially equivalent health insurance coverage in connection with new employment or self-employment (such period from the termination date through the earliest of (A) through (C), the COBRA Payment Period). If you become eligible for coverage under another employers group health plan or otherwise cease to be eligible for COBRA during the period provided in this clause, you must immediately notify the Company of such event, and all payments and obligations under this clause shall cease; and
(iii) acceleration of the service-based vesting of the Option and any other equity grants you may hold as of the date of termination, to the extent then outstanding, unvested and, if applicable, unexercised or unsettled, as to the number of shares subject to such equity grants that would have vested in accordance with the applicable service-based vesting schedule as if you had been in service for an additional twelve (12) months as of your termination date (based upon full months of service).
Page 2 of 6
Offer of Employment: Rita I. Jain, M.D.
If, (1) at any time on or within 12 months following the effective date of a Change in Control (as defined in Exhibit C), (2) (i) the Company terminates your employment without Cause, and other than as a result of your death or disability, or (ii) you terminate your employment with the Company for Good Reason (as defined in Exhibit C), and (3) such termination constitutes a Separation from Service, then subject to your obligations below, you shall be entitled to receive the following severance benefits (collectively, the CIC Severance Benefits and together with the Non-CIC Severance Benefits, the Severance Benefits):
(i) a lump sum cash payment consisting of an amount equal to twelve (12) months of your then current base salary, less all applicable withholdings and deductions (the Lump Sum Salary Payment);
(ii) a lump sum cash payment consisting of an amount equal to your target Annual Bonus, with such bonus determined assuming all applicable performance objectives were obtained at target levels for the applicable year (the Lump Sum Bonus Payment);
(iii) payment of your COBRA premiums as described above during the COBRA Payment Period, subject to the terms set forth above; and
(iv) acceleration of the service-based vesting of the Option and any other equity grants you may hold as of the date of termination, to the extent then outstanding, unvested and, if applicable, unexercised or unsettled, such that you will be deemed fully vested as to the service-based vesting requirement thereof as of your termination date.
Notwithstanding the foregoing, if any of the Companys applicable health benefits are self-funded as of the date of your Separation from Service or the Company cannot provide the foregoing COBRA benefits in a manner that is compliant with applicable law, then, instead of providing the COBRA premiums in the manner described in either clause (ii) of the Non-CIC Severance Benefits or clause (iii) of the CIC Severance Benefits, the Company will instead pay to you the applicable amount as a taxable monthly payment for the COBRA Payment Period (or any remaining portion thereof). You will be solely responsible for all matters relating to continuation of coverage under COBRA, including, without limitation, the election of such coverage and, except to the extent the Company pays COBRA premiums on your behalf, the timely payment of premiums.
Your receipt of any such Severance Benefits is conditioned upon (a) your continuing to comply with your obligations under your Confidential Information Agreement; and (b) your delivering to the Company an effective, general release of claims in favor of the Company in a form acceptable to the Company (the Release) within 60 days following your termination date. The Salary Continuation, if applicable, will be paid in equal installments on the Companys regular payroll schedule and will be subject to applicable tax withholdings; provided, however, that no payments will be made prior to the date on which the Release is effective. Within 60 days following your Separation from Service (but in no event later than March 15 of the year following the year in which the Separation from Service occurred), and subject to the Release becoming effective on or prior to such date, the Company will pay you in a lump sum the Salary Continuation or the Lump Sum Salary Payment and Lump Sum Bonus Payment, as applicable, and other applicable Severance Benefits that you would have received on or prior to such date under the original schedule but for the delay while waiting for the effectiveness of the Release, with the balance of the Salary Continuation, if applicable, and other applicable Severance Benefits being paid as originally scheduled. In no event will you be entitled to both the Non-CIC Severance Benefits and the CIC Severance Benefits. For the avoidance of doubt, the vesting acceleration set forth in the Severance Benefits will not apply to any equity award(s) to the extent vesting thereof is subject to the satisfaction of any performance-based metrics (other than remaining in continuous service with the Company or certain of its affiliates). Any vesting acceleration and other vesting terms of any such performance-based equity awards, if any, will be governed by the terms of the equity plan under which they are granted and the terms and conditions set forth in the award agreements governing such awards.
Additional Tax Matters
The provisions relating to Code Section 409A and Code Section 280G each as defined and set forth in Exhibit C hereto are incorporated herein by reference and form part of this letter.
Page 3 of 6
Offer of Employment: Rita I. Jain, M.D.
Dispute Resolution
To aid in the rapid and economical resolution of disputes that may arise between us, you and the Company agree that any and all disputes, claims, or demands in any way arising from or relating to this offer letter agreement, your employment with the Company, or the termination of your employment with the Company, including but not limited to any statutory claims, shall be resolved, to the fullest extent permitted by law, pursuant to the Federal Arbitration Act, 9 U.S.C. § 1-16, by final, binding and confidential arbitration in San Francisco, California conducted before a single arbitrator by JAMS, Inc. (JAMS) or its successor, under the then-applicable JAMS rules. You acknowledge that by agreeing to this arbitration procedure, you and the Company waive the right to resolve any such dispute, claim or demand through a trial by jury or judge or by administrative proceeding. In addition, all claims, disputes, or causes of action under this section, whether by you or the Company, must be brought in an individual capacity, and shall not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The arbitrator may not consolidate the claims of more than one person or entity, and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences regarding class claims or proceedings are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class shall proceed in a court of law rather than by arbitration. This paragraph shall not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and are not preempted by the Federal Arbitration Act (collectively, the Excluded Claims). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be publicly filed with a court, while any other claims will remain subject to mandatory arbitration. You will have the right to be represented by legal counsel at any arbitration proceeding. Questions of whether a claim is subject to arbitration under this agreement shall be decided by the arbitrator. Likewise, procedural questions which grow out of the dispute and bear on the final disposition are also matters for the arbitrator. The arbitrator shall: (a) have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be available under applicable law in a court proceeding; and (b) issue a written statement signed by the arbitrator regarding the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrators essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees. Nothing in this offer letter is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any arbitration. Any awards or orders in such arbitrations may be entered and enforced as judgments in the federal and state courts of any competent jurisdiction.
Miscellaneous
Federal immigration law requires that we verify your right to work legally in the United States and your employment at ChemoCentryx is contingent upon satisfactory proof of your right to work legally in the United States. On the back of the Form I-9, you will find Lists of Acceptable Documents that both identify and establish employment eligibility. Please bring in either one document from List A or one document from list B and list C on your first day of work. These document(s) must be provided to us no later than three business days after your date of hire or your employment relationship with ChemoCentryx may be terminated.
ChemoCentryx also participates in E-Verify. All newly-hired employees are queried through this electronic system established by the Department of Homeland Security (DHS) and the Social Security Administration (SSA) to verify their identity and employment eligibility. If you will not be present at a ChemoCentryx office location on your first day of employment, please contact Human Resources for instructions.
Page 4 of 6
Offer of Employment: Rita I. Jain, M.D.
This letter, together with its exhibits, forms your complete and exclusive agreement with the Company concerning the subject matter hereof. The employment terms in this letter supersede any other representations or agreements made to you by any party, whether oral or written. The terms of this agreement cannot be changed (except with respect to those changes expressly reserved to the Companys discretion in this letter) without a written agreement signed by you and a duly authorized officer of the Company. This agreement is to be governed by the laws of the state of California without reference to conflicts of law principles. In case any provision contained in this agreement shall, for any reason, be held invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect the other provisions of this agreement, and such provision will be reformed, construed and enforced so as to render it valid and enforceable consistent with the general intent of the parties insofar as possible under applicable law. With respect to the enforcement of this agreement, no waiver of any right hereunder shall be effective unless it is in writing. For purposes of construction of this agreement, any ambiguity shall not be construed against either party as the drafter. This agreement may be executed in more than one counterpart, and signatures transmitted via facsimile or PDF shall be deemed equivalent to originals.
ChemoCentryx requires all staff in the United States to be fully vaccinated (FDA approved vaccines or vaccines that have FDA Emergency Use Authorization) from COVID-19 as a condition of employment. In accordance with applicable laws, ChemoCentryx will provide reasonable accommodations to staff members who qualify on the basis of a medical reason or a sincerely held religious belief, practice, or observance.
Your employment at ChemoCentryx is contingent upon satisfactory completion of professional references, drug test and background checks. You agree to assist as needed and to complete any documentation at the Companys request to meet these conditions. If you wish to accept employment at ChemoCentryx under the terms contained above, please sign and date this letter and the Confidential Information Agreement by October 8, 2021, and return to the Senior Vice President, Human Resources. This offer of employment will terminate if it is not accepted, signed, and returned by this date.
We look forward to you joining ChemoCentryx and to a productive and enjoyable work relationship.
Very best regards,
/s/ Kari Leetch |
Kari E. Leetch |
Senior Vice President, Human Resources |
Page 5 of 6
Offer of Employment: Rita I. Jain, M.D.
Understood and Accepted: | ||||
/s/ Rita Jain |
10/5/2021 | |||
Employee Signature | Date | |||
10/5/2021 | ||||
Start Date |
Enclosures
Exhibit A Employee Confidential Information and Inventions Assignment Agreement
Exhibit B State Specific Notifications/Modification (As Applicable)
Exhibit C Definitions and Additional Tax Matters
Page 6 of 6
Exhibit 99.1
ChemoCentryx Appoints Rita I. Jain, M.D. as Executive Vice President, Chief Medical Officer
Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product
SAN CARLOS, Calif., October 11, 2021 ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors (where she has served since March of 2019) as an executive employee director. Dr. Jain, a board certified rheumatologist, brings more than 20 years of drug development experience leading multiple global programs across early and late stages of development.
Today we bolster our strength as an organization - and across a range of extremely important therapeutic areas - by bringing Rita Jain to the ChemoCentryx leadership team, said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. We welcome her; we cite her impressive track record in drug development with years of experience in leading highly innovative programs. All of these qualities, combined with her dedication to making a fundamental difference in patients lives, are a perfect complement to our ChemoCentryx mission.
Through my role on ChemoCentryxs Board of Directors Ive seen firsthand the value of the science and promise of the companys pipeline. Im excited to now join the leadership team and play a larger role in driving these assets forward, particularly at such a transformational time, said Dr. Jain. I am impressed with the companys successful execution to date and look forward to supporting its future achievements
Dr Jain previously served as Chief Medical officer of Immunovant, Inc. and prior to that Senior Vice President and Chief Medical Officer of Akebia Therapeutics, Inc. Before joining Akebia, Dr. Jain was Vice President of Mens and Womens Health and Metabolic Development at AbbVie, Inc., and prior to that served in various leadership roles including Divisional Vice President at Abbott Laboratories. Dr. Jain led the design and execution of multiple late-stage programs, including for Orilissa® and Oriahnn®. She has also led programs across a diverse set of therapeutic areas including inflammation, pain, immunology and nephrology, among others.
Before Abbott, she held management positions in the Arthritis, Inflammation and Pain Group at G.D. Searle (acquired by Pharmacia and subsequently Pfizer). Earlier in her career, Dr. Jain was a faculty member at North Shore University Hospital in New York, with an academic appointment as Assistant Professor of Medicine, New York University School of Medicine.
Dr. Jain received her B.S. in biology from LIU/C.W. Post and her M.D. from the State University of New York at Stony Brook School of Medicine. Dr. Jain completed her medical training in internal medicine at Staten Island University Hospital followed by a Fellowship in Rheumatology at North Shore University Hospital and a Clinical Research Fellowship at the University of Texas Southwestern Medical Center, Dallas.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOSTM (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis
Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information visit www.chemocentryx.com
Contacts:
Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com
Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com
Investors:
Burns McClellan, Inc.
Lee Roth
212.213.0006
lroth@burnsmc.com
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end
Document and Entity Information |
Oct. 05, 2021 |
---|---|
Cover [Abstract] | |
Amendment Flag | false |
Entity Central Index Key | 0001340652 |
Document Type | 8-K |
Document Period End Date | Oct. 05, 2021 |
Entity Registrant Name | ChemoCentryx, Inc. |
Entity Incorporation State Country Code | DE |
Entity File Number | 001-35420 |
Entity Tax Identification Number | 94-3254365 |
Entity Address, Address Line One | 835 Industrial Road |
Entity Address, City or Town | San Carlos |
Entity Address, State or Province | CA |
Entity Address, Postal Zip Code | 94070 |
City Area Code | (650) |
Local Phone Number | 210-2900 |
Written Communications | false |
Soliciting Material | false |
Pre Commencement Tender Offer | false |
Pre Commencement Issuer Tender Offer | false |
Security 12b Title | Common Stock, par value $0.001 per share |
Trading Symbol | CCXI |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | false |
RHY_U=3_ 102P,$% @ .S),4Y>*NQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/: (7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU M1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'FR-9V87YTC'?8Q']>5=2(6NF9MYEJ6R!F_236P@ MR*2*Y U+2X 3[+O,&@EXN1:T/9=1,92L88!.R '<(Y_ A^[<#K3P&]'@!6^A C(,=D",Y1]X MVXG\-/O4(VSV'T:$%'J6"V&%E+C?Z/F-:#R!+ ]=R_$)'0.M#,,SQ;;!<.AH MQ$5V9://8:Q#B'/Z3XRQJK"$52Q;#X&'' E<)S"D&IND53 >"CVN*!.L>@PL M(:EU&*ADMW,JI]=V<,TB]RI#FJ,,:&T'X:-:"Q4&L&]R( DNR94;4EWI>::W M=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$% @ .S),4R0>FZ*M ^ $ M !H !X;"]? +7_OR4Z?:!1W;J"V\R1&:P;* M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( #LR3%-ED'F2&0$ M ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@ MIAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1 M?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI M>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UP MZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T M,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^ MD &PO=&AE;64O=&AE;64Q M+GAM;%!+ 0(4 Q0 ( #LR3%,V>F&B- 0 $(0 8 " M@0T( !X;"]W;W)K &PO &PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " [,DQ399!YDAD! #/ P $P M @ &-$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #7 %$P ! end
!5>B
M5>O$=^!.XQ!PMV3/1VZ8[<=UMWW1^E%FN[/ EY5L2[F#_WH-[2#N^39C2-W+AQPVN?*GF6ZKQ)HZ?
M42KT_U+%OR4SOJ66;%3]$S[9](V5Z)NR91-IKFH!##\6'KO>I8>:^_O[=;J;-EUJ
MF0W0:C1VZWA[Q(U(FWO>C2PT]R9BJCP1QGI^4_/4%&?1;#8:G8P6(U=1 KTW
MZ[]_>#_$#GA5AB;FH9>-D\1Z+57[=;B;-I1&M5O-U[=,P;7('KA9U[8);4.8
ML/C][<7[1?-X=?M%TWJL>6C&2D]Y# #"GCK51JO:>I7KI KP*'24PN6N?O9R
M>,#!Y6U3+7$1[_HEF+K&K^KVIFNZ'BP(^0IA7W ??\"O7+1D: XP$.\U7S/U9?!&5R^@5%J2K^4E8D8!NFR7FQ1-PI*^4+GR_:)'5I*Z;E:9$97)E5U07M-3*F61:/,?)$5RSFMJG2ESC^8I*GM
MC5$_V<2H-Z6I;$K?C0@T:R;JI4EMHC/U>C*A[\L]@I$VMY5:%)6M;4'\P:*W
M-LM4:19%66.WZQGA6JFKA/#,1NVJ2N>I6[C=V"T]&@[P+:]T6Y3OU:0LYEB\
MQ!N)GA:$59;9O*#=LR+1V%W=SFQF5%WJ&X/OI@3$M,ETF2T!1TQ -3,Z_;71
M)6E9G!B+P*
M*5-2-Z)G7ACQ7OQXP'S,GJ=9D(V>:(HBV.8F60.M)WXW-4MY9N>V9@D?T=>I
MO;%IPX8F]0H(JSN!\D'[\7E"GV>6_PE#TCY7D+DAT>&'(@M ^"!R/3DZ$\R9
M2!-;5K5PA+9C$A RK6L
)U(3'HPE#X
MTN5\IW^3&.2)O%!